Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway

Abstract Background Current challenges in Chimeric Antigen Receptor (CAR) -T cell therapy for hematological cancers include T cell exhaustion and limited persistence, which contribute to cancer relapse. Methods The effects of Axitinib, a VEGFR inhibitor, on the biological functions of CAR-T cells in...

Full description

Saved in:
Bibliographic Details
Main Authors: Suwan Wu, Yiyi Wei, Yingqi Qiu, Kexin Ai, Mu Chen, Hao Wang, Honghao Zhang, Qingyan Cen, Peiyun Liao, Xiangyang Ding, Xiaoling Xie, Yuhua Li
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-024-05907-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849314825759358976
author Suwan Wu
Yiyi Wei
Yingqi Qiu
Kexin Ai
Mu Chen
Hao Wang
Honghao Zhang
Qingyan Cen
Peiyun Liao
Xiangyang Ding
Xiaoling Xie
Yuhua Li
author_facet Suwan Wu
Yiyi Wei
Yingqi Qiu
Kexin Ai
Mu Chen
Hao Wang
Honghao Zhang
Qingyan Cen
Peiyun Liao
Xiangyang Ding
Xiaoling Xie
Yuhua Li
author_sort Suwan Wu
collection DOAJ
description Abstract Background Current challenges in Chimeric Antigen Receptor (CAR) -T cell therapy for hematological cancers include T cell exhaustion and limited persistence, which contribute to cancer relapse. Methods The effects of Axitinib, a VEGFR inhibitor, on the biological functions of CAR-T cells in vitro and in vivo were investigated by comparing CAR-T cells pre-treated ex vivo with Axitinib, as well as utilizing a B-ALL mouse model. Real-time quantitative PCR and Western blotting were employed to detect the expression of molecules related to differentiation, exhaustion, and the Wnt pathway in CAR-T cells. Flow cytometry was used to assess changes in CAR-T cell differentiation, exhaustion, activation, apoptosis, proliferation, and cytokine secretion. Western blotting and flow cytometry were used to assess changes in VEGFR expression. Bioluminescence imaging, flow cytometry, and immunohistochemistry (IHC) analysis were used to evaluate changes in tumor burden in mice receiving different treatments, while hematoxylin and eosin (H&E) staining were used to monitor histological changes in the liver and spleen of mice. Results Axitinib treatment notably reduced CAR-T cell exhaustion and terminal differentiation both under tonic signaling and tumor antigen exposure scenarios. Furthermore, CAR-T cells pretreated with Axitinib demonstrated enhanced anti-tumor efficacy and prolonged survival in vivo. Mechanistically, Axitinib treatment upregulated the Wnt/β-catenin signaling pathway in CAR-T cells. Using agonists/inhibitors of the Wnt/β-catenin pathway could respectively mimic or counteract the effects of Axitinib on CAR-T cell exhaustion and differentiation. CAR-T cells treated with Axitinib can inhibit the VEGFR2 pathway. CAR-T cells treated with anti-VEGFR2 antibody can activate the Wnt/β-catenin pathway and prevent CAR-T cell exhaustion. Conclusion Axitinib confers resistance to exhaustion in CAR-T cells by modulating the Wnt/β-catenin signaling pathway.
format Article
id doaj-art-b6b9b8ad157e4140b7968c18d18c4607
institution Kabale University
issn 1479-5876
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj-art-b6b9b8ad157e4140b7968c18d18c46072025-08-20T03:52:19ZengBMCJournal of Translational Medicine1479-58762025-04-0123111710.1186/s12967-024-05907-zInhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathwaySuwan Wu0Yiyi Wei1Yingqi Qiu2Kexin Ai3Mu Chen4Hao Wang5Honghao Zhang6Qingyan Cen7Peiyun Liao8Xiangyang Ding9Xiaoling Xie10Yuhua Li11Department of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityDepartment of Hematology, Zhujiang Hospital, Southern Medical UniversityAbstract Background Current challenges in Chimeric Antigen Receptor (CAR) -T cell therapy for hematological cancers include T cell exhaustion and limited persistence, which contribute to cancer relapse. Methods The effects of Axitinib, a VEGFR inhibitor, on the biological functions of CAR-T cells in vitro and in vivo were investigated by comparing CAR-T cells pre-treated ex vivo with Axitinib, as well as utilizing a B-ALL mouse model. Real-time quantitative PCR and Western blotting were employed to detect the expression of molecules related to differentiation, exhaustion, and the Wnt pathway in CAR-T cells. Flow cytometry was used to assess changes in CAR-T cell differentiation, exhaustion, activation, apoptosis, proliferation, and cytokine secretion. Western blotting and flow cytometry were used to assess changes in VEGFR expression. Bioluminescence imaging, flow cytometry, and immunohistochemistry (IHC) analysis were used to evaluate changes in tumor burden in mice receiving different treatments, while hematoxylin and eosin (H&E) staining were used to monitor histological changes in the liver and spleen of mice. Results Axitinib treatment notably reduced CAR-T cell exhaustion and terminal differentiation both under tonic signaling and tumor antigen exposure scenarios. Furthermore, CAR-T cells pretreated with Axitinib demonstrated enhanced anti-tumor efficacy and prolonged survival in vivo. Mechanistically, Axitinib treatment upregulated the Wnt/β-catenin signaling pathway in CAR-T cells. Using agonists/inhibitors of the Wnt/β-catenin pathway could respectively mimic or counteract the effects of Axitinib on CAR-T cell exhaustion and differentiation. CAR-T cells treated with Axitinib can inhibit the VEGFR2 pathway. CAR-T cells treated with anti-VEGFR2 antibody can activate the Wnt/β-catenin pathway and prevent CAR-T cell exhaustion. Conclusion Axitinib confers resistance to exhaustion in CAR-T cells by modulating the Wnt/β-catenin signaling pathway.https://doi.org/10.1186/s12967-024-05907-zChimeric antigen receptor T cellsAcute lymphoblastic leukemiaVascular endothelial growth factor receptorDifferentiationExhaustion
spellingShingle Suwan Wu
Yiyi Wei
Yingqi Qiu
Kexin Ai
Mu Chen
Hao Wang
Honghao Zhang
Qingyan Cen
Peiyun Liao
Xiangyang Ding
Xiaoling Xie
Yuhua Li
Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
Journal of Translational Medicine
Chimeric antigen receptor T cells
Acute lymphoblastic leukemia
Vascular endothelial growth factor receptor
Differentiation
Exhaustion
title Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
title_full Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
title_fullStr Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
title_full_unstemmed Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
title_short Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway
title_sort inhibition of vegf signaling prevents exhaustion and enhances anti leukemia efficacy of car t cells via wnt β catenin pathway
topic Chimeric antigen receptor T cells
Acute lymphoblastic leukemia
Vascular endothelial growth factor receptor
Differentiation
Exhaustion
url https://doi.org/10.1186/s12967-024-05907-z
work_keys_str_mv AT suwanwu inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT yiyiwei inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT yingqiqiu inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT kexinai inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT muchen inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT haowang inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT honghaozhang inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT qingyancen inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT peiyunliao inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT xiangyangding inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT xiaolingxie inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway
AT yuhuali inhibitionofvegfsignalingpreventsexhaustionandenhancesantileukemiaefficacyofcartcellsviawntbcateninpathway